Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H20O9 |
Molecular Weight | 356.3246 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]3(O[C@@H]1OC=C2C(=O)OCC=C2[C@H]1C=C)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O
InChI
InChIKey=DUAGQYUORDTXOR-GPQRQXLASA-N
InChI=1S/C16H20O9/c1-2-7-8-3-4-22-14(21)9(8)6-23-15(7)25-16-13(20)12(19)11(18)10(5-17)24-16/h2-3,6-7,10-13,15-20H,1,4-5H2/t7-,10-,11-,12+,13-,15+,16+/m1/s1
Molecular Formula | C16H20O9 |
Molecular Weight | 356.3246 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Gentiopicrin is a naturally occurring iridoid glycoside. It is a bioactive component of gentian species of medical plants. It has proved to be the strongest inhibitor of myeloperoxidase. It could be absorbed rapidly in mice, but with a low bioavailability, and could distribute to tissues extensively. Gentiopicrin has been reported to be effective against inflammatory conditions such as rheumatoid arthritis, liver illness, fever, digestive and intestinal disorders. Gentiopicrin treatment can exert anti-inflammatory effects on experimental acute colitis through attenuating the expression levels of TNF-α, IL-1β, IL-6, iNOS and COX-2, and it may present the therapeutic potential in the treatment of colitis. The drug inhibits reserpine-induced pain/depression dyad by downregulating GluN2B receptors in the amygdala. Gentiopicrin injection was approved by SFDA for the treatment of acute jaundice and chronic active hepatitis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15537172
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23419353 |
|||
Target ID: P05181 Gene ID: 1571.0 Gene Symbol: CYP2E1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23419353 |
|||
Target ID: CHEMBL2439 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22521634 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27394986 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Determination of iridoids and triterpenes in herb of Swertia pseudochinesis by RP-HPLC]. | 2007 Dec |
|
Gentiopicrin-producing endophytic fungus isolated from Gentiana macrophylla. | 2009 Aug |
|
Antimicrobial activity of Gentiana lutea L. extracts. | 2009 May-Jun |
|
Anti-apoptotic activity of gentiopicroside in D-galactosamine/lipopolysaccharide-induced murine fulminant hepatic failure. | 2010 Oct 6 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27394986
Mice: 200, 100, and 50mg/kg once a day for 7days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26116164
50, 500, and 1,500 ug/mL of gentiopicrin exhibited no significant toxicity to chondrocytes (P>0.05) after 24h.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:41:06 GMT 2023
by
admin
on
Fri Dec 15 19:41:06 GMT 2023
|
Record UNII |
0WE09Z21RC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5702
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
606402
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
88708
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
20831-76-9
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
DTXSID40878043
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
0WE09Z21RC
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
C012997
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY | |||
|
244-070-2
Created by
admin on Fri Dec 15 19:41:06 GMT 2023 , Edited by admin on Fri Dec 15 19:41:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |